Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/202322
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Plasma coenzyme Q10 status is impaired in selected genetic conditions |
Autor: | Montero, Raquel; Yubero, Delia; Salgado, María C.; González, María Julieta; Campistol, Jaume; O’Callaghan, Maria del Mar; Pineda, Mercé; Delgadillo, Verónica; Maynou, Joan; Fernandez, Guerau; Montoya, Julio; Ruiz-Pesini, Eduardo; Meavilla, Silvia; Neergheen, Viruna; García-Cazorla, Angels; Navas, Plácido CSIC ORCID; Hargreaves, Iain; Artuch, Rafael | Palabras clave: | Biomarkers Neurology |
Fecha de publicación: | 2019 | Editor: | Springer Nature | Citación: | Scientific Reports 9: 793 (2019) | Resumen: | Identifying diseases displaying chronic low plasma Coenzyme Q10 (CoQ) values may be important to prevent possible cardiovascular dysfunction. The aim of this study was to retrospectively evaluate plasma CoQ concentrations in a large cohort of pediatric and young adult patients. We evaluated plasma CoQ values in 597 individuals (age range 1 month to 43 years, average 11 years), studied during the period 2005–2016. Patients were classified into 6 different groups: control group of healthy participants, phenylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients with other inborn errors of metabolism (IEM), patients with neurogenetic diseases, and individuals with neurological diseases with no genetic diagnosis. Plasma total CoQ was measured by reverse-phase high-performance liquid chromatography with electrochemical detection and ultraviolet detection at 275 nm. ANOVA with Bonferroni correction showed that plasma CoQ values were significantly lower in the PKU and MPS groups than in controls and neurological patients. The IEM group showed intermediate values that were not significantly different from those of the controls. In PKU patients, the Chi-Square test showed a significant association between having low plasma CoQ values and being classic PKU patients. The percentage of neurogenetic and other neurological patients with low CoQ values was low (below 8%). In conclusión, plasma CoQ monitoring in selected groups of patients with different IEM (especially in PKU and MPS patients, but also in IEM under protein-restricted diets) seems advisable to prevent the possibility of a chronic blood CoQ suboptimal status in such groups of patients. | Descripción: | © The Author(s) 2019. | Versión del editor: | http://dx.doi.org/10.1038/s41598-018-37542-2 | URI: | http://hdl.handle.net/10261/202322 | DOI: | 10.1038/s41598-018-37542-2 | E-ISSN: | 2045-2322 |
Aparece en las colecciones: | (CABD) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Plasma_Montero_Art2019.pdf | 1,19 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
15
checked on 15-mar-2024
SCOPUSTM
Citations
26
checked on 24-mar-2024
WEB OF SCIENCETM
Citations
26
checked on 22-feb-2024
Page view(s)
168
checked on 29-mar-2024
Download(s)
120
checked on 29-mar-2024